Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma

AIMS: Omalizumab, a subcutaneously administered anti-IgE antibody, is effective for moderate-to-severe persistent allergic asthma. The aims were to (i) describe the population pharmacodynamics of free IgE with a mechanism-based, nonlinear, omalizumab–IgE binding model; (ii) deduce a target-free IgE...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Lowe, Philip J, Tannenbaum, Stacey, Gautier, Aurelie, Jimenez, Pablo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Blackwell Science Inc 2009
Gaiak:
Pharmacokinetic Dynamic Relationships
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2732941/
https://ncbi.nlm.nih.gov/pubmed/19660004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2009.03401.x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak